Onyx Bridge Wealth Group LLC Invests $393,000 in Amgen Inc. (NASDAQ:AMGN)

Onyx Bridge Wealth Group LLC purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,363 shares of the medical research company’s stock, valued at approximately $393,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Amgen by 1.7% during the third quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock worth $3,133,000 after buying an additional 193 shares in the last quarter. Diversified Trust Co raised its stake in Amgen by 76.8% in the fourth quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after purchasing an additional 16,376 shares in the last quarter. Nicolet Advisory Services LLC raised its stake in Amgen by 4.4% in the third quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock valued at $745,000 after purchasing an additional 117 shares in the last quarter. Platform Technology Partners raised its stake in Amgen by 7.4% in the third quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock valued at $1,567,000 after purchasing an additional 402 shares in the last quarter. Finally, Traynor Capital Management Inc. raised its stake in Amgen by 9.5% in the fourth quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock valued at $5,455,000 after purchasing an additional 1,650 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Trading Up 2.4 %

Shares of Amgen stock traded up $6.18 during midday trading on Friday, reaching $268.93. The company had a trading volume of 3,380,330 shares, compared to its average volume of 2,077,465. The stock has a fifty day moving average price of $276.90 and a 200 day moving average price of $281.26. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The firm has a market cap of $144.25 billion, a PE ratio of 21.53, a P/E/G ratio of 2.44 and a beta of 0.58. Amgen Inc. has a fifty-two week low of $211.71 and a fifty-two week high of $329.72.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, topping analysts’ consensus estimates of $4.66 by $0.05. The company had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The firm’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.09 earnings per share. On average, equities analysts anticipate that Amgen Inc. will post 19.45 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 annualized dividend and a yield of 3.35%. The ex-dividend date of this dividend is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

Analyst Ratings Changes

AMGN has been the subject of a number of analyst reports. Leerink Partnrs downgraded Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, February 7th. TD Cowen decreased their target price on Amgen from $370.00 to $360.00 and set a “buy” rating on the stock in a research report on Wednesday. UBS Group decreased their target price on Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a research report on Wednesday. Oppenheimer reiterated an “outperform” rating and issued a $350.00 target price on shares of Amgen in a research report on Thursday, February 1st. Finally, Raymond James initiated coverage on Amgen in a research report on Thursday, March 28th. They issued a “market perform” rating on the stock. Ten equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.